Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

Nature

Volumn 428, Issue 6980, 2004, Pages 332-337

  Wendel, Hans Guido ^a   De Stanchina, Elisa ^a   Fridman, Jordan S ^a,e   Malina, Abba ^b   Ray, Sagarika ^a   Kogan, Scott ^c   Cordon Cardo, Carlos ^d   Pelletier, Jerry ^b   Lowe, Scott W ^a  

^a Simons Center for Quantitative Biology   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DRUG PRODUCTS; GENES; TUMORS;

CANCER THERAPY; MUTATIONS;

ONCOLOGY;

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ELONGATION FACTOR; ELONGATION FACTOR 4E; ENZYME INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; INITIATION FACTOR 4E; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P53; PROTEIN SERINE THREONINE KINASE;

MEDICINE;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; EMBRYO; FEMALE; GENE MUTATION; GENOTYPE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR MODEL; ANIMAL; B CELL LYMPHOMA; C57BL MOUSE; CANCER TRANSPLANTATION; CELL DIVISION; CELL SURVIVAL; DISEASE COURSE; DRUG ANTAGONISM; GENETICS; METABOLISM; PATHOLOGY;

ANIMALIA; MURINAE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EUKARYOTIC INITIATION FACTOR-4E; EUKARYOTIC INITIATION FACTOR-4G; FEMALE; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1642586272     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature02369     Document Type: Article

References (30)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Johnstone, R. W., Ruefli, A. A. & Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164 (2002).
3. Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K. & Donner, D. B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277, 5484-5489 (2002).
4. Datta, S. R., Brunet, A. & Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927 (1999).
5. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489-501 (2002).
6. Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15, 356-362 (1997).
7. Sakai, A., Thieblemont, C., Wellmann, A., Jaffe, E. S. & Raffeld, M. PTEN gene alterations in lymphoid neoplasms. Blood 92, 3410-3415 (1998).
8. Min, Y. H. et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17, 995-997 (2003).
9. Andjelkovic, M. et al. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 272, 31515-31524 (1997).
10. Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533-538 (1985).
11. Schmitt, C. A. et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289-298 (2002).
12. Schmitt, C. A., Rosenthal, C. T. & Lowe, S. W. Genetic a analysis of chemoresistance in primary murine lymphomas. Nature Med. 6, 1029-1035 (2000).
13. Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346 (2002).
14. Huang, S. & Houghton, P. J. Targeting mTOR signalling for cancer therapy. Curr. Opin. Pharmacol. 3, 371-377 (2003).
15. Plas, D. R., Talapatra, S., Edinger, A. L., Rathmell, J. C. & Thompson, C. B. Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J. Biol. Chem. 276, 12041-12048 (2001).
16. Edinger, A. L. & Thompson, C. B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 2276-2288 (2002).
17. Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314-10319 (2001).
18. Grunwald, V. et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62, 6141-6145 (2002).
19. +/- mice. Proc. Natl Acad. Sci. USA 98, 10320-10325 (2001).
20. Hosoi, H. et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 59, 886-894 (1999).
21. Schmelzle, T. & Hall, M. N. TOR, a central controller of cell growth. Cell 103, 253-262 (2000).
22. Lazaris-Karatzas, A., Montine, K. S. & Sonenberg, N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345, 544-547 (1990).
23. Polunovsky, V. A. et al. Translational control of the antiapoptotic function of Ras. J. Biol. Chem. 275, 24776-24780 (2000).
24. Hershey, J. W. B. & Miyamoto, S. in Translational Control of Gene Expression (eds Sonenberg, N., Hershey, J. W. B. & Mathews, M. B.) 637-654 (Cold Spring Harbor, New York, 2000).
25. Grolleau, A. et al. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J. Biol. Chem. 277, 22175-22184 (2002).
26. Rajasekhar, V. K. et al. Oncogenic Ras and Akt signalling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell 12, 889-901 (2003).
27. Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670-2677 (1999).
28. Yang, M. et al. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc. Natl Acad. Sci. USA 97, 1206-1211 (2000).
29. Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C. & Pandolfi, P. P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nature Genet. 27, 222-224 (2001).
30. de Stanchina, E. et al. E1A signalling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12, 2434-2442 (1998).